RxDoctor Payments Data

Nachiket Apte

Clinical Cardiac Electrophysiology · Louisville, KYNPI 1821355322

Payments from drug & device makers

What this record shows

The money is spread across several categories — grants (58.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 69.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $32,901 and has fallen 88.7% since, to $3,719 in 2025.

$44,151in general payments, 2019–2025

Across 217 payments — averaging $203.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$31K
  • Abbott$6K
  • Boston Scientific$4K
  • Biotronik Inc.$2K
  • Philips North America LLC$654
  • Cvrx, Inc.$494
  • plus $665 from 7 others

What the payments were for

  • Consulting fees$4751%
  • Grants$25,90159%
  • Travel & lodging$8,81820%
  • Food & beverage$8,67420%
  • Education$2831%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,151 in reported general payments places this provider in the 75th percentile of 57 clinical cardiac electrophysiology providers in Kentucky.

See all clinical cardiac electrophysiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$154,587
Medicare patients
697
Services billed
2,498

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban199$204,818
XareltoRivaroxaban36$35,326
MultaqDronedarone Hcl20$23,176
EntrestoSacubitril/Valsartan20$22,067
JardianceEmpagliflozin16$17,529
FarxigaDapagliflozin Propanediol17$16,483
Flecainide Acetate35$2,674
Metoprolol Succinate117$1,651
Amiodarone Hcl43$1,566
Acebutolol Hcl11$726
SotalolSotalol Hcl33$690
Bumetanide17$624
Hydralazine Hcl22$489
Cephalexin30$356
Carvedilol42$272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$32$35,32636 claims
Boehringer IngelheimJardiance$22$17,52916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 57 clinical cardiac electrophysiology providers in Kentucky.

Other clinical cardiac electrophysiology in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →